Immunwork has synthesized a number of new drug candidates and is designing a series of new drugs based on our T-E molecular-design platforms. While our T-E pharmaceuticals are new drug entities, the targeting and/or the effector elements in many of these drug candidates are based on existing drugs, which have been approved for clinical uses or studied extensively. Our goal is to create a class of new drugs and to improve many existing drugs with higher efficacy and safety (E/S) profiles. We also aspire to revive some drugs, which have failed in clinical trials, by empowering them with better targeting and/or effector functions. The product candidates described on this website have potential applications in treating disease indications in the areas of oncology, autoimmune diseases, osteoporosis, infectious diseases, CNS diseases, pathological blood clots, and organ transplant rejection.
 |